Therapeutic composition comprising a botulinum neurotoxin

Abstract

A pharmaceutical preparation comprising one of the botulinum neurotoxins from Clostridium botulinum of types A, B, C, D, E, F or G or a mixture of two or more of these neurotoxins, wherein the neurotoxin or the mixture of neurotoxins is free of the complexing proteins which naturally form the botulinum neurotoxin complexes together with the neurotoxins.

1 . A pharmaceutical preparation comprising a  Clostridium botulinum  neurotoxin selected from types A, B, C, D, E, F or G or a mixture of two or more of these neurotoxins, wherein the neurotoxin or the mixture of the neurotoxins is free of complexing proteins which naturally form complexes with botulinum neurotoxin. 
     
     
         2 . The pharmaceutical preparation of  claim 1 , wherein the neurotoxin or mixture of neurotoxins exhibits reduced antigenicity compared to botulinum toxin complexes. 
     
     
         3 . The pharmaceutical preparation of  claim 1  which is non-antigenic. 
     
     
         4 . The pharmaceutical preparation of  claim 1 , wherein the neurotoxin is a natural neurotoxin or the mixture of neurotoxins comprises a natural neurotoxin. 
     
     
         5 . The pharmaceutical preparation of  claim 1 , wherein the neurotoxin is a recombinant neurotoxin or the mixture of neurotoxins comprises a recombinant neurotoxin. 
     
     
         6 . The pharmaceutical preparation of  claim 1 , wherein the neurotoxin is from  Clostridium botulinum  type A or B. 
     
     
         7 . The pharmaceutical preparation of  claim 1 , wherein the mixture of the neurotoxins comprises a neurotoxin from  Clostridium botulinum  type A or B. 
     
     
         8 . The pharmaceutical preparation of  claim 1 , wherein the mixture of the neurotoxins consists essentially of a neurotoxin from  Clostridium botulinum  type A or B. 
     
     
         9 . The pharmaceutical preparation of  claim 1 , wherein the neurotoxin does not comprise hemagglutinins. 
     
     
         10 . The pharmaceutical preparation of  claim 1 , which is in the form of an injectable aqueous solution. 
     
     
         11 . The pharmaceutical preparation of  claim 1 , which is lyophilized.